On January 3, 2025, Changchun GeneScience Pharmaceutical Co., Ltd. (GenSci) and Beijing Dongfang Yunjia Pharmaceutical Co., Ltd. (Dongfang Yunjia) announced that their jointly developed Class 1.1 innovative traditional Chinese medicine, Pediatric Golden Cough-Relief Granules (brand name: JinSaike?), has been approved for marketing by China NMPA. This medication is indicated for children aged 3 to 7 with acute cough caused by phlegm-heat obstructing the lungs, offering an improved treatment option for managing acute bronchitis-related cough in pediatric clinical practice.

GenSci and Dongfang YunJia have reached a strategic partnership on Pediatric Golden Cough Granules (JinSaike?) to jointly promote the commercialization process. This collaboration marks a significant step in the company's strategic expansion within the pediatric respiratory field.

Looking ahead, GenSci's Respiratory and Integrated Medicine Division will prioritize the field of children's respiratory health and focus on diseases such as respiratory infections and allergic immune disorders. By integrating diagnosis and treatment, the division seeks to deliver innovative products and cutting-edge therapeutic solutions, providing exceptional support to clinical practices and improving the lives of young patients.